title: Intermittent treatment with D-penicillamine is effective in lower doses and with fewer adverse effects in patients with rheumatoid arthritis.
abstract: OBJECTIVE
  To determine whether intermittent rather than daily administration of D-penicillamine (D-Pen) would effectively reduce the incidence of adverse effects without significantly diminishing the clinical benefits.
  
  
  METHODS
  We conducted an open prospective trial comparing daily and intermittent schedules. Among 76 Japanese patients with rheumatoid arthritis (RA), 37 underwent daily treatment with D-Pen while 39 were given D-Pen intermittently (every Monday, Wednesday, and Friday).
  
  
  RESULTS
  The mean D-Pen dose was 166.8 and 99.4 mg/day for daily and intermittent groups, respectively, the difference being highly significant (p < 0.0001, Mann-Whitney's U test). The incidence of adverse effects was significantly lower in the intermittent group. Both schedules significantly reduced the activity of RA, as evaluated by clinical and laboratory variables. No significant differences were observed in the degree of improvement between the 2 schedules.
  
  
  CONCLUSIONS
  Intermittent therapy with D-Pen is an effective treatment for patients with RA and its higher degree of flexibility can lead to maximum efficacy for management of patients with RA.
authors.affiliation: Institute of Rheumatology, Tokyo Women's Medical College, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hakoda
authors.forename: A
authors.initials: A
authors.lastname: Taniguchi
authors.forename: N
authors.initials: N
authors.lastname: Kamatani
authors.forename: T
authors.initials: T
authors.lastname: Akahoshi
authors.forename: S
authors.initials: S
authors.lastname: Kashiwazaki
mesh_terms: D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003627:Data Interpretation, Statistical; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D011239:Prednisolone; D010396:Penicillamine